Fresenius Kabi Canada Ltd Pharmaceutical Import Profile — Canada (DGFT 2022–2026)

Name: Fresenius Kabi Canada Ltd Pharmaceutical Import Records from India — 2 Products, $8.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Fresenius Kabi Canada Ltd — Pharmaceutical Importer Profile (2026) | 2 Products, $8.3M Trade | TransData Nexus

Fresenius Kabi Canada Ltd

Pharmaceutical Importer · Canada · Cardiovascular Focus · $8.3M Total Trade · DGFT Verified

Fresenius Kabi Canada Ltd is a pharmaceutical importer based in Canada with a total trade value of $8.3M across 2 products in 2 therapeutic categories. Based on 167 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Fresenius Kabi Canada Ltd sources from 4 verified Indian suppliers, with Biological E. Limited accounting for 83.4% of imports.

Fresenius Kabi Canada Ltd — Import Portfolio & Supplier Network

Fresenius Kabi Canada Ltd import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Fresenius Kabi Canada Ltd?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Biological E. Limited	$3.9M	96	83.4%
Piramal Pharma Limited	$549.8K	21	11.9%
Biological E Limited	$208.0K

What Formulations Does Fresenius Kabi Canada Ltd Import?

Formulation	Value	Ships
51000441 - enoxaparin sodium injection	$1.1M	24
51000440 - enoxaparin sodium injection	$616.1K	14
51000444 - enoxaparin sodium injection	$462.3K	14
51000446 - enoxaparin sodium injection	$300.0K	6
51000447 - enoxaparin sodium injection	$263.1K	8
51000441 - enoxoparin sodium injection,USP(40MG/04ML	$250.0K	5
51000445 - enoxaparin sodium injection	$244.6K	8
Isoflurane 250m vet other desc.as per	$200.0K	4
51000446 - enoxaparin sodium injection,USP (100MG/1ML)	$150.0K	3
51000445 - enoxaparin sodium injection,USP (80MG/0.8ML	$144.1K	3
Isoflurane 250ML other desc.as per invoice attch.green card no.420/vsez	$139.0K	4
Isoflurane 250ML other desc as per invoice attch green card no 420 vsez dt 10 05	$100.0K	2
51000444 - enoxaparin sodium injection,USP(60MG/0.6ML)	$99.9K	2
Isoflurane 100ML human other desc.as	$64.0K	7
51000441 - enoxoparin sodium injection	$58.0K	2

Fresenius Kabi Canada Ltd imports 31 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Enoxaparin	Cardiovascular	$4.3M	87	2.1%	8
2	Sodium	Nutritional Supplements	$4.0M	80	1.1%	15

Fresenius Kabi Canada Ltd imports 2 pharmaceutical products across 2 categories into Canada totaling $8.3M.

Fresenius Kabi Canada Ltd — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Fresenius Kabi Canada Ltd is a Canadian subsidiary of the global healthcare company Fresenius Kabi, specializing in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. The company is headquartered in Toronto, Ontario, and is dedicated to supplying high-quality, cost-effective pharmaceutical products and services to Canadians. Their extensive product portfolio includes intravenous specialty and generic medicines, transfusion technologies, infusion therapies, parenteral nutrition, biosimilars, complex formulations, and related medical devices.

Fresenius Kabi Canada plays a significant role in the Canadian pharmaceutical distribution network by providing essential medicines and technologies to healthcare providers across the country. Their commitment to improving patient care is evident through their diverse product offerings and continuous investment in advanced manufacturing and distribution facilities. For instance, in October 2018, the company opened a state-of-the-art compounding center in Mississauga, Ontario, to meet the increasing demand for large batches of compounded medications in Canadian hospitals.

2Distribution Network

Fresenius Kabi Canada Ltd operates a robust distribution network to ensure the timely delivery of its products across Canada. The company's Canadian headquarters are located at 165 Galaxy Blvd. Suite 100, Toronto, Ontario M9W 0C8. Additionally, in October 2018, Fresenius Kabi opened a new 35,000-square-foot compounding center in Mississauga, Ontario, to enhance its manufacturing capabilities and meet the growing demand for compounded medications in Canadian hospitals.

While specific details about other warehouse locations and logistics capabilities are not publicly disclosed, Fresenius Kabi's global presence and integrated supply chain network suggest a well-established infrastructure to support its operations in Canada. The company's commitment to investing in North American manufacturing and technology further underscores its dedication to meeting the needs of the Canadian market.

3Industry Role

Fresenius Kabi Canada Ltd serves as a pharmaceutical importer and distributor within Canada's healthcare sector. The company imports finished pharmaceutical formulations from various suppliers, including those in India, to meet the needs of Canadian healthcare providers. Their product portfolio encompasses intravenous specialty and generic medicines, transfusion technologies, infusion therapies, parenteral nutrition, biosimilars, complex formulations, and related medical devices.

By importing and distributing these products, Fresenius Kabi Canada plays a crucial role in ensuring the availability of essential medicines and technologies for critically and chronically ill patients across the country. Their operations contribute to the overall efficiency and effectiveness of Canada's pharmaceutical supply chain, supporting healthcare providers in delivering quality care to patients.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Fresenius Kabi Canada Ltd

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Fresenius Kabi Canada Ltd's sourcing strategy reveals a significant concentration in its supplier base, particularly from India. The company has imported a total of $8.3 million USD worth of finished pharmaceutical formulations from India across 167 shipments, encompassing 31 unique formulations. The top two products imported are Enoxaparin ($4.3 million, 2.1% share) and Sodium ($4.0 million, 1.1% share), indicating a heavy reliance on these specific products.

This sourcing pattern suggests a strategic choice to focus on high-demand, high-value products that align with the company's therapeutic focus areas. However, the heavy reliance on a limited number of products and suppliers may pose risks related to supply chain disruptions, price fluctuations, and regulatory changes in the supplier's country. The stability of the relationship with Indian suppliers, particularly BIOLOGICAL E. LIMITED, which accounts for 83.4% of the shipments, is crucial for maintaining a consistent supply of these key products.

2Supply Chain Resilience

Fresenius Kabi Canada Ltd's supply chain resilience is influenced by its sourcing strategy, which heavily depends on a limited number of suppliers and products. The company's reliance on BIOLOGICAL E. LIMITED for a significant portion of its imports indicates a concentrated supply chain, which may be vulnerable to disruptions such as production issues, regulatory changes, or geopolitical events in India.

Importing Pharmaceuticals into Canada — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Canada

1Regulatory Authority & Framework

In Canada, the primary regulatory authority overseeing pharmaceutical imports is Health Canada, which is responsible for ensuring that all pharmaceutical products meet the necessary safety, efficacy, and quality standards before they are authorized for sale. The Food and Drugs Act and its associated regulations govern the importation, distribution, and sale of pharmaceutical products in Canada.

For Indian generics to be marketed in Canada, they must undergo a rigorous evaluation process by Health Canada. This process includes the submission of a New Drug Submission (NDS) or Abbreviated New Drug Submission (ANDS), depending on the product's nature. The evaluation assesses the product's safety, efficacy, quality, and compliance with Canadian standards. Once approved, the product is granted a Notice of Compliance (NOC), allowing it to be marketed in Canada.

2Import Licensing & GMP

Import licensing requirements in Canada are managed by Health Canada. Companies importing pharmaceutical products must obtain a Drug Establishment License (DEL), which authorizes them to import, distribute, and sell drugs in Canada. This license ensures that the importer complies with all regulatory requirements and maintains appropriate records.

Good Manufacturing Practice (GMP) certification is essential for pharmaceutical products imported into Canada. Health Canada recognizes GMP certifications from various regulatory bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certifications from recognized authorities to guarantee product quality and safety.

Fresenius Kabi Canada Ltd — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Fresenius Kabi Canada Ltd's product strategy focuses on two primary therapeutic areas: cardiovascular and nutritional supplements. The company's imports from India align with these areas, with Enoxaparin and Sodium being the top two products sourced. This strategic focus indicates a commitment to addressing critical health conditions prevalent in the Canadian population.

The demand for these products is driven by the high incidence of cardiovascular diseases and the need for nutritional support in critically ill patients. By concentrating on these therapeutic areas, Fresenius Kabi Canada aims to meet the specific healthcare needs of Canadians and enhance patient outcomes.

2Sourcing Profile

Fresenius Kabi Canada Ltd's sourcing strategy emphasizes the procurement of generic drugs, particularly in the cardiovascular and nutritional supplement categories. The company imports finished pharmaceutical formulations from India, focusing on products that align with its therapeutic areas of interest. This approach allows Fresenius Kabi Canada to offer cost-effective solutions while maintaining product quality.

India's well-established pharmaceutical manufacturing industry, with its adherence to recognized GMP standards, makes it

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Fresenius Kabi Canada Ltd

What products does Fresenius Kabi Canada Ltd import from India?

Fresenius Kabi Canada Ltd imports 2 pharmaceutical products across 2 categories. Top imports: Enoxaparin ($4.3M), Sodium ($4.0M).

Who supplies pharmaceuticals to Fresenius Kabi Canada Ltd from India?

Fresenius Kabi Canada Ltd sources from 4 verified Indian suppliers. The primary supplier is Biological E. Limited (83.4% of imports, $3.9M).

What is Fresenius Kabi Canada Ltd's total pharmaceutical import value?

Fresenius Kabi Canada Ltd's total pharmaceutical import value from India is $8.3M, based on 167 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Fresenius Kabi Canada Ltd focus on?

Fresenius Kabi Canada Ltd imports across 2 categories. The largest: Cardiovascular (52.1%), Nutritional Supplements (47.9%).

Get Full Fresenius Kabi Canada Ltd Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.